- Home
- OPT vs SITC Comparison
OPT vs SITC Comparison
Compare OPT & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- SITC
- Stock Information
- Founded
- OPT 1984
- SITC 1965
- Country
- OPT Australia
- SITC United States
- Employees
- OPT N/A
- SITC N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- SITC Real Estate Investment Trusts
- Sector
- OPT Health Care
- SITC Real Estate
- Exchange
- OPT Nasdaq
- SITC Nasdaq
- Market Cap
- OPT 767.9M
- SITC 830.0M
- IPO Year
- OPT 2020
- SITC 1993
- Fundamental
- Price
- OPT $3.60
- SITC $15.31
- Analyst Decision
- OPT Strong Buy
- SITC Hold
- Analyst Count
- OPT 1
- SITC 10
- Target Price
- OPT $12.00
- SITC $39.03
- AVG Volume (30 Days)
- OPT 9.2K
- SITC 1.6M
- Earning Date
- OPT 08-30-2024
- SITC 02-11-2025
- Dividend Yield
- OPT N/A
- SITC 4.25%
- EPS Growth
- OPT N/A
- SITC 757.51
- EPS
- OPT N/A
- SITC 13.71
- Revenue
- OPT $261,859.00
- SITC $451,683,000.00
- Revenue This Year
- OPT N/A
- SITC N/A
- Revenue Next Year
- OPT $46,864.64
- SITC N/A
- P/E Ratio
- OPT N/A
- SITC $1.12
- Revenue Growth
- OPT N/A
- SITC N/A
- 52 Week Low
- OPT $1.79
- SITC $14.84
- 52 Week High
- OPT $5.45
- SITC $64.44
- Technical
- Relative Strength Index (RSI)
- OPT 52.65
- SITC 37.02
- Support Level
- OPT $3.15
- SITC $14.84
- Resistance Level
- OPT $3.39
- SITC $15.73
- Average True Range (ATR)
- OPT 0.17
- SITC 0.35
- MACD
- OPT 0.05
- SITC 0.14
- Stochastic Oscillator
- OPT 72.31
- SITC 52.25
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.